Cullinan Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Cullinan Therapeutics

07/05/2024 12:52

* Cullinan Therapeutics Inc  CGEM.OQ   CGEM.O  is expected
to show
no change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Cullinan Therapeutics
Inc is
for a loss of 99 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Cullinan
Therapeutics Inc is $30.00​, above​ its last closing price
of $28.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.95       -0.96      -0.54     Beat    43.8
 Sep. 30 2023  -0.92       -0.92      -0.91     Beat    1.3
 Jan. 1 0001   -0.90       -0.97      -0.82     Beat    15.5​
 Mar. 31 2023  -1.00       -0.98      -1.42     Missed  -44.9
 ​​Dec.        -0.63       -0.66      -0.59     Beat    11.3
 31 2022                                                
 Sep. 30 2022  -0.95       -0.97      -0.54     Beat    44.1​
 Jan. 1 0001   5.42        5.42       3.77      Missed  -30.4
 Mar. 31 2022  -0.62       -0.61      -0.27     Beat    55.7
 This summary was machine generated May 7 at 11:51 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)